Khiron Life Sciences Corp. (TSXV:KHRN), an integrated medical cannabis company with its core operations in Colombia, announced today that the Company has signed an exclusive agreement with the Colombian Association of Palliative Care (ACCP), the leading network of pain and palliative care specialists in Colombia.

The Latin American Association of Palliative Care (ALCP) estimates 4 million people need palliative care treatment within the Latin American market. This agreement forms the initial step towards addressing the medical needs of these individuals and enables Khiron to provide doctors and caregivers with direct access to specialized e-learning platforms, information, research, and educational resources about extract-based medical cannabis treatment alternatives. As part of this agreement, Khiron will be the exclusive medical cannabis company marketing to, and participating in, ACCP events and activities in Colombia.


Dr. Maria Fernanda Arboleda, Medical Director of Khiron stated, “As a pain and palliative care physician, I have learned from my clinical experience that medical cannabis can be utilized effectively as a complementary therapy in reducing pain and related symptoms of palliative care patients. This important relationship with the Colombian Association of Palliative Care will allow us to support the use of medical cannabis in this population and improve the standards of care and patients´ safety in Colombia.”

Dr. Claudia Buitrago, President of the ACCP stated, “We are convinced that working with Khiron will bring educational tools that are fundamental to our medical associates being able to prescribe medical cannabis and allows them to have a higher degree of confidence that their recommendations are responsible and informed.”

The field of palliative care in Colombia is at the development stage. Doctors, staff and interdisciplinary teams are working to inform and train specialist care providers, with the objective of reducing the pain and associated symptoms of palliative care patients. The recent International Palliative Care Congress, held in Medellin, Colombia, attracted more than 400 doctors and specialists in pain and palliative care, and included a presentation by Dr. Arboleda.

Dr. Maria Fernanda Arboleda is the co-author of ‘Cannabis in Palliative Care: current challenges and practical recommendations’, a comprehensive analysis of the role of Cannabinoid-based medicines in palliative care treatment. This review, which was recently published in the Annals of Palliative Medicine, can be found at http://apm.amegroups.com/article/view/20097/21242

About The Colombian Association of Palliative Care (ACCP)

Founded in 1996, The Palliative Care Association of Colombia is an non-profit interdisciplinary association of qualified professionals that have experience in the clinical aspects, research, and organization of Palliative Care with a powerful drive to come together to work towards the development and the implementation of palliative care in all levels of health care in Colombia.

The ACCP leads changes in palliative care access, and provides scientific and humanized quality care, providing all universities with palliative care training programs, as well as in undergraduate medicine, nursing and psychology. For information visit www.paliativoscolombia.org

About Khiron Life Sciences Corp.

Khiron Life Sciences Corp.  (TSXV: KRHN, OTCQB: KHRNF, Frankfurt: A2JMZC) (“Khiron” or the “Company”) is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming one of the first Colombian based medical cannabis company to trade on any exchange globally.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Further information on Khiron Life Sciences can be found at www.khiron.ca.

Forward-Looking Statements

This press release may contain certain forward-looking information and statements (“forward-looking information”) within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Filing Statement which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

For further information: Investor Contacts: Chris Naprawa, President, T: +1 (416) 705-1144, E: cnaprawa@khiron.ca; Darren Collins, Chief Financial Officer, T: +1 (705) 527-3564, E: dcollins@khiron.ca; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: jpacker@khiron.ca

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN) for an Investor Presentation. 

Source: www.newswire.ca

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less